Navigation Links
Two Studies Test Impact of Drugs to Slow Progression of Type 1 Diabetes
Date:6/27/2011

5 people, ages 3 to 45, with newly diagnosed type 1 diabetes. Participants were randomized into three groups to receive two or three doses of GAD-alum or alum alone over 4 to 12 weeks. During one year of treatment, the vaccine showed no evidence of preserving insulin secretion.

Adverse effects were minimal for both drugs, especially among children, who account for the majority of people with type 1 diabetes.  

"We learn something important from every study, and we build on everything we learn.  Both positive and negative studies help us develop more effective strategies to prevent and treat type 1 diabetes," said TrialNet Study Group Chair Jay Skyler, M.D. "We will continue to follow people in both studies.  It is still early, but there is good reason to believe that some of the drugs being developed to alter immune responses, either alone or in combination with other therapies, will lead to treatments that prevent, postpone, or stop progression of type 1 diabetes."

Type 1 diabetes is an autoimmune disease that accounts for 5 to 10 percent of diagnosed cases of diabetes in the United States—up to 2.5 million people. It develops when a person's own immune system destroys beta cells in the pancreas. Beta cells sense blood glucose and produce the hormone insulin, which regulates glucose levels and converts it to energy. Formerly called juvenile onset diabetes, type 1 diabetes usually develops in children and young adults. To maintain good control of their blood glucose levels, people with this form of diabetes typically need three or more insulin injections a day or treatment with an insulin pump, as well as careful monitoring of blood glucose and attention to diet and exercise.  Well controlled glucose is critical to preventing or delaying serious damage to the eyes, nerves, kidneys, heart, and blood vessels.

The destruction of insulin producing cells by the immune system begins well before the symptoms of diabet
'/>"/>

SOURCE TrialNet
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Studies Show Effect of BYDUREON™ on A1C and Weight for Up to Three Years
2. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
3. Best of ASCO Features Two Studies Led by US Oncology Research Affiliated Physicians
4. Data from Clinical Studies of bioTheranostics CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
5. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
6. Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
7. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
8. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
9. Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
10. Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO
11. New Studies Support CardioFocus HeartLight™ Endoscopic Ablation Systems Notable Treatment Results for Paroxysmal Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Research and Markets  has announced the addition ... report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... to inflammation and pain in the human body,s joints such ... causes inflammation of the tissues that surround the joints and ... RA begin slowly, usually just mild pain around the joints ...
(Date:7/28/2014)... -- Syneron Medical Ltd. (NASDAQ: ELOS ), a ... new PicoWay® device has received CE Mark indication to ... lesions on any skin type. PicoWay is a new ... wavelengths, which utilizes Syneron,s proprietary PicoWay technology to deliver ... of a second, known as picosecond pulses. Syneron will ...
(Date:7/28/2014)... -- Concord Medical Services Holdings Limited ("Concord Medical" or ... specialty hospital management solution provider and operator of the ... China , today announced that on ... special cash dividend of US$0.30 per ordinary share (or ... outstanding ordinary shares. The total expense for the special ...
Breaking Medicine Technology:Global Rheumatoid Arthritis Drugs Market 2014-2018 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4Concord Medical Declares Special Dividend 2
... PORTSMOUTH, N.H., Aug. 4, 2011 Novocure, a ... it has entered into a long-term supply agreement ... engineering and manufacturing conglomerate ITT Corporation (NYSE: ITT). ... ceramic components used to manufacture the disposable electrodes ...
... Texas, Aug. 4, 2011 Healthpoint Biotherapeutics today ... clinical trial investigating the efficacy of HP802-247 in ... living cell suspension containing keratinocytes and fibroblasts. The ... of two cell concentrations and two dosing frequencies ...
Cached Medicine Technology:Novocure Announces Long-Term Supply Agreement With ITT Corporation for Ceramic Sensor Technology 2Novocure Announces Long-Term Supply Agreement With ITT Corporation for Ceramic Sensor Technology 3Positive Results for Phase IIb Trial of Unique Cell-Based Therapy in Venous Leg Ulcers 2Positive Results for Phase IIb Trial of Unique Cell-Based Therapy in Venous Leg Ulcers 3Positive Results for Phase IIb Trial of Unique Cell-Based Therapy in Venous Leg Ulcers 4
(Date:7/28/2014)... Cape Regional Medical Center, is ... technology solution in an effort to streamline its ... with their New Jersey health information exchange (NJSHINE). ... in New Jersey, serves the local population and ... of inpatient and outpatient services. With a strong ...
(Date:7/28/2014)... 28, 2014 (HealthDay News) --,The more chronic medical conditions ... expectancy may be, a new study claims. ... health issues, scientists at Johns Hopkins Bloomberg School of ... explain why gains in life expectancy are slowing in ... such as diabetes, kidney disease and heart failure is ...
(Date:7/28/2014)... Reinberg HealthDay Reporter MONDAY, ... and heart rhythm irregularities are more likely to get a ... In fact, the study of more than 16,000 people found ... likely to get a pacemaker than those without the memory-robbing ... why folks with dementia are so much more likely to ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Parker Waichman LLP, ... fighting to ensure that the heroes of 9/11 are never ... has announced an important deadline. According to a VCF ... with a covered cancer on or before October 12, 2012 ... 2014. First responders and others who were allegedly injured by ...
(Date:7/28/2014)... expecting somethinglike the meal you,ve ordered at a ... rhythms sweep through your brain. , These ... a symphony of cellsboth excitatory and inhibitoryplaying together ... been debated, gamma waves have been associated with ... have been tied to schizophrenia, Alzheimer,s disease, autism, ...
Breaking Medicine News(10 mins):Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 3Health News:Memory relies on astrocytes, the brain's lesser known cells 2Health News:Memory relies on astrocytes, the brain's lesser known cells 3
... in mice shows promise for possible use in treating Alzheimer's ... study. ,Alzheimer's disease is the most common form of ... speech deterioration, and behavioral changes. The main factor in the ... toxic to the brain. ,Researchers say they have found ...
... steps you take to prevent heart attack may also ... risk factors like high blood pressure and high cholesterol ... and can cause death of brain cells over time. ... designed to slow the progression of mixed dementia, vascular ...
... Researchers say most of the existing drugs on the ... are derived from soil bacteria hence researchers feel that ... miracle drugs.// ,More than 1 million microorganisms ... to a life-saving treatment for some of our deadliest ...
... have identified a protein that essentially blocks HIV replication, ... it is not as effective at stopping HIV, say ... issue of Nature. The team, headed by Joseph Sodroski, ... and Infectious Diseases (NIAID). ,"Identification of this ...
... have optic nerve damage are at increased risk for ... with visual impairment. The participants had their sleep-wakefulness cycles ... with those of 12 young subjects with normal sight. ... more likely to have daytime sleepiness than those with ...
... panoramic X-rays can identify postmenopausal women with low skeletal ... taken for the diagnosis of conditions affecting the teeth ... the mandibular cortical shape and width and refer the ... more than 300 women who had no symptoms of ...
Cached Medicine News:
... 2.2 offers extremely high resolution treatment capability ... an exceptionally wide 78° field of view. ... critical evaluation of the optic nerve head ... of the macula and disc. Redesigned to ...
... is excellent for critically evaluating and ... macular degeneration, retinal vascular occlusions, diabetic ... other retinal conditions. It is ideal ... conditions providing excellent magnification combined with ...
... 130° QuadrAspheric lens has grown in popularity ... preferred wide field fundus laser lens. Its ... advantage over competitive wide field lenses for ... of use. This lens is excellent for ...
... Wide Field Lens combines exceptional ... magnification. The enhanced double aspheric ... high resolution stereo views of ... These unique features make it ...
Medicine Products: